| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.84(B) |
| Last
Volume: |
1,347,016 |
Avg
Vol: |
2,431,686 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 17.5 |
| Insider 6 Months : 18.9 |
| Insider 3/6 Months : 36.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
| Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
3 |
4 |
4 |
| Total Shares Sold |
88,818 |
210,838 |
601,659 |
1,021,249 |
| Total Sell Value |
$1,938,121 |
$4,689,450 |
$12,908,109 |
$20,266,173 |
| Total People Sold |
5 |
7 |
9 |
12 |
| Total Sell Transactions |
6 |
9 |
17 |
28 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Morrissey Michael M |
President and CEO |
• • – |
2018-11-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
17,647 |
90,000 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-11-15 |
4 |
S |
$17.22 |
$430,500 |
D/D |
(25,000) |
107,647 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-11-15 |
4 |
OE |
$4.42 |
$110,500 |
D/D |
25,000 |
132,647 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-11-15 |
4 |
D |
$17.45 |
$302,810 |
D/D |
(17,353) |
107,647 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2018-11-15 |
4 |
D |
$17.45 |
$205,474 |
D/D |
(11,775) |
316,513 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2018-11-15 |
4 |
D |
$17.45 |
$135,482 |
D/D |
(7,764) |
155,741 |
|
- |
|
| Haley Patrick J. |
Sr. Vice President, Commercial |
• – – |
2018-11-15 |
4 |
D |
$17.45 |
$158,900 |
D/D |
(9,106) |
97,011 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2018-11-15 |
4 |
D |
$17.45 |
$160,523 |
D/D |
(9,199) |
117,197 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2018-11-15 |
4 |
D |
$17.45 |
$101,419 |
D/D |
(5,812) |
248,638 |
|
- |
|
| Haley Patrick J. |
Sr. Vice President, Commercial |
• – – |
2018-11-07 |
4 |
S |
$17.32 |
$346,400 |
D/D |
(20,000) |
104,917 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-11-02 |
4 |
AS |
$17.49 |
$658,964 |
D/D |
(37,499) |
125,000 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-11-02 |
4 |
OE |
$5.04 |
$188,995 |
D/D |
37,499 |
162,499 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2018-11-01 |
4 |
AS |
$14.16 |
$169,920 |
D/D |
(12,000) |
328,288 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2018-11-01 |
4 |
OE |
$5.04 |
$60,480 |
D/D |
12,000 |
340,288 |
|
- |
|
| Scangos George A |
Director |
– • – |
2018-11-01 |
4 |
AS |
$14.14 |
$366,400 |
D/D |
(25,000) |
1,511,981 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-10-01 |
4 |
AS |
$17.82 |
$222,768 |
D/D |
(12,501) |
125,000 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-10-01 |
4 |
OE |
$5.04 |
$63,005 |
D/D |
12,501 |
137,501 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2018-10-01 |
4 |
AS |
$17.77 |
$213,240 |
D/D |
(12,000) |
328,288 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2018-10-01 |
4 |
OE |
$5.04 |
$60,480 |
D/D |
12,000 |
340,288 |
|
- |
|
| Scangos George A |
Director |
– • – |
2018-10-01 |
4 |
AS |
$17.86 |
$446,500 |
D/D |
(25,000) |
1,536,981 |
|
- |
|
| Scangos George A |
Director |
– • – |
2018-09-24 |
4 |
S |
$16.85 |
$421,250 |
D/D |
(25,000) |
1,561,981 |
|
- |
|
| Schwab Gisela Md |
Pres Prod Dev & Med Aff & CMO |
• – – |
2018-09-04 |
4 |
AS |
$18.53 |
$416,925 |
D/D |
(22,500) |
328,288 |
|
- |
|
| Schwab Gisela Md |
Pres Prod Dev & Med Aff & CMO |
• – – |
2018-09-04 |
4 |
OE |
$5.50 |
$123,750 |
D/D |
22,500 |
350,788 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-08-20 |
4 |
AS |
$17.79 |
$1,604,216 |
D/D |
(90,000) |
125,000 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2018-08-20 |
4 |
OE |
$5.50 |
$495,000 |
D/D |
90,000 |
215,000 |
|
- |
|
1438 Records found
|
|
Page 30 of 58 |
|
|
0.03 (0.14%) 
